Abstract: Methods, systems, and apparatus consistent with the present invention use a beam of laser energy to concentrically form an optical preform from two or more concentric glass objects, such as two glass tubes or a hollow glass tube and a solid glass rod. The glass objects are placed in a concentric configuration where the outer object has an inner surface that is placed proximate to an outer surface of the inner object. Once these are assembled, a beam of laser energy is generated, positioned, and applied to a starting point in the gap defined by the inner surface and the outer surface. Once the laser beam is applied and is reflecting down into the gap, the beam of laser energy is moved relative to the starting point as the beam is concurrently applied. This heats the inner surface and outer surface so that the two objects can be joined to form the optical preform. In another aspect of the invention, a coating layer is disposed within the gap and can be heated by the laser as it is applied within the gap.

Abstract: In accordance with the present invention, commercials are provided to a subscriber at the start of or during their use of an interactive television application. Further in accordance with the invention, a subscriber may select to pay for use of the interactive television application by watching a specified amount of commercials in connection with use of the application. The subscriber can thereby reduce or avoid any additional payment for such services. In accordance with another aspect of the invention, the subscriber is prompted to determine the payment method preferred by the subscriber payment method includes receiving commercials as an option in lieu of or in addition to traditional payment methods such as pay-per-view, pay-per-use pay-per-play and subscription based.

Abstract: The present invention relates to purine analogs that inhibit, inter alia, protein kinases, G-proteins and polymerases. In addition, the present invention relates to methods of using such purine analogs to inhibit protein kinases, G-proteins, polymerases and other cellular processes and to treat cellular proliferative diseases.

Abstract: The invention provides compounds having the structure: where, R1 is a member selected from the group consisting of H and NH2; R2 is member selected from the group consisting of H, CO2H, OH and halogen; and R3 is a member selected from the group consisting of CO2H, NH2 and halogen. Also provided are methods of using the compounds and formulations containing the compounds.

Abstract: The present invention relates to purine analogs that inhibit, inter alia, protein kinases, G-proteins and polymerases. In addition, the present invention relates to methods of using such purine analogs to inhibit protein kinases, G-proteins, polymerases and other cellular processes and to treat cellular proliferative diseases.

Abstract: This invention provides compositions and methods for generating components of protein biosynthetic machinery including orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases. Methods for identifying orthogonal pairs are also provided. These components can be used to incorporate unnatural amino acids into proteins in vivo.

Abstract: The generation of selective inhibitors for specific protein kinases would provide new tools for analyzing signal transduction pathways and possibly new therapeutic agents. We have invented an approach to the development of selective protein kinase inhibitors based on the unexpected binding mode of 2,6,9-trisubstituted purines to the ATP binding site of human CDK2. The most potent inhibitor, purvalanol B (IC50=6 nM), binds with a 30-fold greater affinity than the known CDK2 inhibitor, flavopiridol. The cellular effects of this class of compounds were examined and compared to those of flavopiridol by monitoring changes in mRNA expression levels for all genes in treated cells of Saccharomyces cerevisiae using high-density oligonucleotide probe arrays.

Abstract: The invention provides methods and compositions for in vivo incorporation of unnatural amino acids. Also provided are compositions including proteins with unnatural amino acids.

Abstract: Methods, systems, and apparatus consistent with the present invention use laser energy for thermally processing a quartz object using a beam of laser energy. Once placed in a configuration where the laser beam can be applied to an exterior surface of the quartz object, one or more laser beams are applied to a starting point on the surface. The laser beams may have the same or different wavelengths, energy levels and/or focal lengths. As the surface is heated by the laser energy, the surface is eventually pierced by the beam and a channel forms within the quartz object. As the channel deepens to access an inner portion of the object, the energy of the beam is altered to thermally process or selectively heat the inner portion. After processing the inner portion, the channel is typically closed by fusion welding the walls of the channel (or the channel and quartz filler material) using the beam.

Abstract: The present invention relates to the use of polypeptides of the MIP (macrophage inflammatory proteins) class for the treatment of diseases involving a pathological change of thrombocytopolesis, especially for the treatment of thrombocytopenia.

Abstract: Methods, systems, and apparatus consistent with the present invention use a beam of laser energy to concentrically form an optical preform from two or more concentric glass objects, such as two glass tubes or a hollow glass tube and a solid glass rod. The glass objects are placed in a concentric configuration where the outer object has an inner surface that is placed proximate to an outer surface of the inner object. Once these are assembled, a beam of laser energy is generated, positioned, and applied to a starting point in the gap defined by the inner surface and the outer surface. Once the laser beam is applied and is reflecting down into the gap, the beam of laser energy is moved relative to the starting point as the beam is concurrently applied. This heats the inner surface and outer surface so that the two objects can be joined to form the optical preform. In another aspect of the invention, a coating layer is disposed within the gap and can be heated by the laser as it is applied within the gap.

Abstract: Methods, systems, and apparatus consistent with the present invention apply one or more laser beams to a glass object, such as a tube. The beams may have differing wavelengths, energy levels, and/or focal length characteristics. As the beam (single or multiple) penetrates the glass tube, it creates a channel. The beam is provided through the channel to a starting point on a region of the glass tube, usually the region below an inside diameter surface of the tube. In one embodiment, the beam is used to selectively heat a reactant gas within the tube to deposit a coating/dopant layer on the inside diameter surface. In another embodiment, the coating layer is already present and the beam selectively heats the layer causing thermal diffusion of the coating material into the glass tube at the region being heated.

Abstract: The present invention relates to purine analogs that inhibit, inter alia, protein kinases, G-proteins and polymerases. In addition, the present invention relates to methods of using such purine analogs to inhibit protein kinases, G-proteins, polymerases and other cellular processes and to treat cellular proliferative diseases.

Abstract: Compounds of formula 1: ##STR1## wherein R.sub.1 is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro;R.sub.2 is hydroxy, amino, or lower alkoxy;R.sub.3 is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amnino-acyl;R.sub.4 is H or lower alkyl; and pharmaceutically acceptable salts and esters thereof; are effective inhibitors of GSK3.

Abstract: The present invention relates to complexes of the CDK2 protein with proteins identified as interacting with CDK2 by a modified yeast two hybrid assay system. The proteins identified to interact with CDK2 are cyclin H, cyclin I, ERH, and two gene products, hsReq*-1 and hsReq*-2, which are splice variants of the gene hsReq. Thus, the invention provides complexes of CDK2 and cyclin H, cyclin I, ERH, hsReq*-1, and hsReq*-2, and derivatives, fragments and analogs thereof. The invention also provides nucleic acids encoding the hsReq*-1 and hsReq*-2, and proteins and derivatives, fragments and analogs thereof. Methods of screening the complexes for efficacy in treating and/or preventing certain diseases and disorders, particularly cancer, atherosclerosis and neurodegenerative disease are also provided.

Abstract: Granular leuco vat-dye preparations containing, as essential components, leuco vat-dye, reducing agents and alkaline metal hydroxide, and the production of said preparations and their use in dyeing cellulose-containing textile materials.

Abstract: Leucoindigo preparations in granule form consisting essentially of leucoindigo and alkali metal hydroxide and production of these preparations and use thereof for dyeing cellulose-containing textile material.

Abstract: Catalytic and reactive polypeptides include a binding site specific for a reactant or reactive intermediate involved in a chemical reaction of interest. The polypeptides further include at least one active functionality proximate the binding site, where the active functionality is capable of catalyzing or chemically participating in the chemical reaction in such a way that the reaction rate is enhanced. Methods for preparing the catalytic peptides include chemical synthesis, site-directed mutagenesis of antibody and enzyme genes, covalent attachment of the functionalities through particular amino acid side chains, and the like.This invention was made with Government support under Grant Contract No. AI-24695, awarded by the Department of health and Human Services, and under Grant Contract No. N 00014-87-K-0256, awarded by the Office of Naval Research. The Government has certain rights in this invention.

Abstract: Catalytic and reactive polypeptides include a binding site specific for a reactant or reactive intermediate involved in a chemical reaction of interest. The polypeptides further include at least one active functionality proximate the binding site, where the active functionality is capable of catalyzing or chemically participating in the chemical reaction in such a way that the reaction rate is enhanced. Methods for preparing the catalytic peptides include chemical synthesis, site-directed mutagenesis of antibody and enzyme genes, covalent attachment of the functionalities through particular amino acid side chains, and the like.

Abstract: Catalytic and reactive polypeptides include a binding site specific for a reactant or reactive intermediate involved in a chemical reaction of interest. The polypeptides further include at least one active functionality proximate the biThis invention was made with Government support under Grant Contract No. AI-24695 awarded by the Department of Health and Human Services, under Grant Contract No. N 00014-87-K-0256, awarded by the Office of Naval Research. The Government has certain rights in this invention, under Grant Contract CHE 8822412 awarded by the National Science Foundation, and under Grant Subcontract C87-101226 awarded by the Department of Energy.